FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2215744541> ?p ?o ?g. }

• W2215744541 abstract "Bone and joint infection in adults arises most commonly as a complication of joint replacement surgery, fracture fixation and diabetic foot infection. The associated morbidity can be devastating to patients and costs the National Health Service an estimated £20,000 to £40,000 per patient. Current standard of care in most UK centres includes a prolonged course (4–6 weeks) of intravenous antibiotics supported, if available, by an outpatient parenteral antibiotic therapy service. Intravenous therapy carries with it substantial risks and inconvenience to patients, and the antibiotic-related costs are approximately ten times that of oral therapy. Despite this, there is no evidence to suggest that oral therapy results in inferior outcomes. We hypothesise that, by selecting oral agents with high bioavailability, good tissue penetration and activity against the known or likely pathogens, key outcomes in patients managed primarily with oral therapy are non-inferior to those in patients treated by intravenous therapy. The OVIVA trial is a parallel group, randomised (1:1), un-blinded, non-inferiority trial conducted in thirty hospitals across the UK. Eligible participants are adults (>18 years) with a clinical syndrome consistent with a bone, joint or metalware-associated infection who have received ≤7 days of intravenous antibiotic therapy from the date of definitive surgery (or the start of planned curative therapy in patients treated without surgical intervention). Participants are randomised to receive either oral or intravenous antibiotics, selected by a specialist infection physician, for the first 6 weeks of therapy. The primary outcome measure is definite treatment failure within one year of randomisation, as assessed by a blinded endpoint committee, according to pre-defined microbiological, histological and clinical criteria. Enrolling 1,050 subjects will provide 90 % power to demonstrate non-inferiority, defined as less than 7.5 % absolute increase in treatment failure rate in patients randomised to oral therapy as compared to intravenous therapy (one-sided alpha of 0.05). If our results demonstrate non-inferiority of orally administered antibiotic therapy, this trial is likely to facilitate a dramatically improved patient experience and alleviate a substantial financial burden on healthcare services. ISRCTN91566927 - 14/02/2013" @default.
• W2215744541 created "2016-06-24" @default.
• W2215744541 creator A5006470271 @default.
• W2215744541 creator A5009075899 @default.
• W2215744541 creator A5009925438 @default.
• W2215744541 creator A5013363997 @default.
• W2215744541 creator A5013471493 @default.
• W2215744541 creator A5015402059 @default.
• W2215744541 creator A5016975236 @default.
• W2215744541 creator A5019479654 @default.
• W2215744541 creator A5028621883 @default.
• W2215744541 creator A5034412976 @default.
• W2215744541 creator A5053114717 @default.
• W2215744541 creator A5057692641 @default.
• W2215744541 creator A5063473429 @default.
• W2215744541 creator A5078904709 @default.
• W2215744541 creator A5080811032 @default.
• W2215744541 creator A5084889315 @default.
• W2215744541 creator A5085215589 @default.
• W2215744541 creator A5086288192 @default.
• W2215744541 creator A5087469402 @default.
• W2215744541 date "2015-12-01" @default.
• W2215744541 modified "2023-09-23" @default.
• W2215744541 title "Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial" @default.
• W2215744541 cites W1988293560 @default.
• W2215744541 cites W1995519304 @default.
• W2215744541 cites W1995624544 @default.
• W2215744541 cites W2046680235 @default.
• W2215744541 cites W2068692974 @default.
• W2215744541 cites W2071090762 @default.
• W2215744541 cites W2073912062 @default.
• W2215744541 cites W2074663566 @default.
• W2215744541 cites W2079575346 @default.
• W2215744541 cites W2082841642 @default.
• W2215744541 cites W2086166821 @default.
• W2215744541 cites W2088293790 @default.
• W2215744541 cites W2098151685 @default.
• W2215744541 cites W2108906598 @default.
• W2215744541 cites W2111293729 @default.
• W2215744541 cites W2114747147 @default.
• W2215744541 cites W2138202752 @default.
• W2215744541 cites W2153225431 @default.
• W2215744541 cites W2159069645 @default.
• W2215744541 cites W2171155970 @default.
• W2215744541 cites W2259654619 @default.
• W2215744541 cites W2260055920 @default.
• W2215744541 cites W2276443311 @default.
• W2215744541 cites W4206408383 @default.
• W2215744541 cites W4241470858 @default.
• W2215744541 cites W4247115368 @default.
• W2215744541 doi "https://doi.org/10.1186/s13063-015-1098-y" @default.
• W2215744541 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4687165" @default.
• W2215744541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26690812" @default.
• W2215744541 hasPublicationYear "2015" @default.
• W2215744541 type Work @default.
• W2215744541 sameAs 2215744541 @default.
• W2215744541 citedByCount "45" @default.
• W2215744541 countsByYear W22157445412016 @default.
• W2215744541 countsByYear W22157445412017 @default.
• W2215744541 countsByYear W22157445412018 @default.
• W2215744541 countsByYear W22157445412019 @default.
• W2215744541 countsByYear W22157445412020 @default.
• W2215744541 countsByYear W22157445412021 @default.
• W2215744541 countsByYear W22157445412022 @default.
• W2215744541 countsByYear W22157445412023 @default.
• W2215744541 crossrefType "journal-article" @default.
• W2215744541 hasAuthorship W2215744541A5006470271 @default.
• W2215744541 hasAuthorship W2215744541A5009075899 @default.
• W2215744541 hasAuthorship W2215744541A5009925438 @default.
• W2215744541 hasAuthorship W2215744541A5013363997 @default.
• W2215744541 hasAuthorship W2215744541A5013471493 @default.
• W2215744541 hasAuthorship W2215744541A5015402059 @default.
• W2215744541 hasAuthorship W2215744541A5016975236 @default.
• W2215744541 hasAuthorship W2215744541A5019479654 @default.
• W2215744541 hasAuthorship W2215744541A5028621883 @default.
• W2215744541 hasAuthorship W2215744541A5034412976 @default.
• W2215744541 hasAuthorship W2215744541A5053114717 @default.
• W2215744541 hasAuthorship W2215744541A5057692641 @default.
• W2215744541 hasAuthorship W2215744541A5063473429 @default.
• W2215744541 hasAuthorship W2215744541A5078904709 @default.
• W2215744541 hasAuthorship W2215744541A5080811032 @default.
• W2215744541 hasAuthorship W2215744541A5084889315 @default.
• W2215744541 hasAuthorship W2215744541A5085215589 @default.
• W2215744541 hasAuthorship W2215744541A5086288192 @default.
• W2215744541 hasAuthorship W2215744541A5087469402 @default.
• W2215744541 hasBestOaLocation W22157445411 @default.
• W2215744541 hasConcept C126322002 @default.
• W2215744541 hasConcept C141071460 @default.
• W2215744541 hasConcept C168563851 @default.
• W2215744541 hasConcept C2780608335 @default.
• W2215744541 hasConcept C3020230634 @default.
• W2215744541 hasConcept C501593827 @default.
• W2215744541 hasConcept C535046627 @default.
• W2215744541 hasConcept C71924100 @default.
• W2215744541 hasConcept C86803240 @default.
• W2215744541 hasConcept C89423630 @default.
• W2215744541 hasConceptScore W2215744541C126322002 @default.
• W2215744541 hasConceptScore W2215744541C141071460 @default.
• W2215744541 hasConceptScore W2215744541C168563851 @default.
• W2215744541 hasConceptScore W2215744541C2780608335 @default.

• next